Related Experiment Video
Updated: Aug 30, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine
Gaetano Marverti1, Maria Giuseppina Monti, Saverio Bettuzzi
1Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica, Università di Modena e Reggio Emilia, Via Campi 287, 41100, Modena, Italy. marverti.gaetano@unimore.it
Abstract:
Cisplatin (DDP)-resistance confers a deficient expression of spermidine/spermine N(1)-acetyltransferase (SSAT) gene in response to the spermine analog N(1),N(12)-bis(ethyl)spermine (BESpm) in the DDP-resistant human ovarian carcinoma cell line (C13*), compared with their parental DDP-sensitive 2008 cells. This SSAT gene deficiency is correlated with a reduced growth sensitivity to spermine analogs. This study was performed to determine whether SSAT gene expression of resistant cells was kept suppressed by labile repressor proteins developed during resistance selection. We show here that inhibitory concentrations of cycloheximide (CHX) and anisomycin (ANISO) differentially affect BESpm-induced SSAT activity in 2008 and in C13* cells in a concentration-dependent manner and allow resistant cells to reach activation levels comparable to those of the sensitive cells. Northern blot analysis revealed that both CHX and ANISO in combination with BESpm caused a synergistic BESpm-mediated accumulation of SSAT mRNA in C13* cells, with respect to each drug alone, while in 2008 cells only a slight increase was observed. The more pronounced effect of inhibitors on the SSAT activity induced by BESpm in the resistant cells was also the result of a more prolonged stabilization of SSAT mRNA and enzyme protein. By contrast, sub-inhibitory concentrations of CHX and ANISO did not significantly stimulate BESpm-induced SSAT transcription and activity. These results suggest that labile repressor proteins, related to DDP-resistance phenotype, play a regulatory role in SSAT gene expression, and further indicate that by overcoming this inhibitory control it is possible to recover BESpm response.
Insights
Cisplatin-resistant ovarian cancer cells show suppressed spermidine/spermine N(1)-acetyltransferase (SSAT) gene expression. Inhibiting repressor proteins with cycloheximide or anisomycin restores SSAT activity and sensitivity to spermine analogs.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Cisplatin-resistant ovarian cancer exhibits deficient spermidine/spermine N(1)-acetyltransferase (SSAT) gene expression.
- This deficiency correlates with reduced sensitivity to spermine analogs like N(1),N(12)-bis(ethyl)spermine (BESpm).
Purpose of the Study:
- To investigate if labile repressor proteins suppress SSAT gene expression in resistant cells.
- To determine if overcoming this suppression can restore sensitivity to spermine analogs.
Main Methods:
- Utilized cisplatin-resistant (C13*) and sensitive (2008) human ovarian carcinoma cell lines.
- Applied inhibitory and sub-inhibitory concentrations of cycloheximide (CHX) and anisomycin (ANISO) with BESpm.
- Analyzed SSAT activity, SSAT mRNA accumulation via Northern blot, and SSAT protein stability.
Main Results:
- Inhibitory concentrations of CHX and ANISO restored BESpm-induced SSAT activity in resistant cells to levels comparable to sensitive cells.
- CHX and ANISO synergistically increased SSAT mRNA accumulation with BESpm in resistant cells, indicating mRNA stabilization.
- Sub-inhibitory concentrations of CHX and ANISO did not significantly affect BESpm-induced SSAT transcription or activity.
Conclusions:
- Labile repressor proteins, linked to cisplatin resistance, regulate SSAT gene expression.
- Overcoming this repression by inhibiting labile repressor proteins can restore sensitivity to spermine analogs in resistant ovarian cancer cells.
Related Concept Videos
Treatment Resistant Cancers
Abnormal Proliferation
Negative Regulator Molecules
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
